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William C. Mackey, MD, Boston, MassBeing selected as the 34th President of The New En-
gland Society for Vascular Surgery is one of the great
honors of my career. My association with this society dates
back to meetings at the old Mount Washington Hotel, with
50 or so stalwarts seated on folding chairs in a tiny meeting
room with a roll-up screen and a single Kodak carousel
projector. In those days, we were a sideshow for the New
England Surgical Society. How far we have come! Our
growth to independence has mirrored the maturation of
our specialty. Witnessing this growth and maturation over
the past 25 years has been a great privilege.
The treatment of carotid artery disease, and specifically
carotid endarterectomy (CEA), has been my major aca-
demic interest in vascular surgery, and so I have been more
than a little threatened by the rise of carotid artery stenting
(CAS). As I am becoming a late-middle-aged dog, new
tricks don’t come easily. As I have watched and studied this
new procedure, I have become convinced that it has a role
in the management of our patients. I simply don’t know
what role. Unfortunately, the currently available clinical
trials don’t help me much. Why?
In this presentation, I want to review with you the
current trials of CAS, assess their value and their shortcom-
ings, look at their common features, and finally, explore
why they fail to define for us the appropriate role for this
new procedure.
Any review of the CAS trials should start with a quick
history of CEA trials and the evidence basis they provide for
the role of endarterectomy in the management of our
patients. I will then briefly present the major published
registries and trials of CAS. I will summarize the findings of
these registries and trials. I will conclude with some reflec-
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470tions on the design of these trials and some recommenda-
tions for future trials.
In 1988, there was significant controversy over the
safety and efficacy of CEA. The results of CEA, as reported
in case series from single institutions, contrasted with the
results from regional surveys. A publication from the
RAND Corporation suggested that approximately one-
third of endarterectomies performed in the United States
were performed for “inappropriate” indications.1 There
were no prospective randomized trials demonstrating safety
or efficacy in symptomatic or asymptomatic patients.
In 1991, The North American Symptomatic Carotid
Endarterectomy Trial (NASCET), along with the parallel
European Carotid Surgery Trial (ECST), proved that CEA
was highly beneficial for those patients with symptoms who
had 70% to 99% carotid stenosis.2 Those symptomatic
patients with 50% to 70% stenosis were later shown to
derive statistically significant benefit from surgery.3 Those
with 50% stenosis derived no benefit from surgery.3 In
addition, NASCET gave us a wealth of information on the
natural history of medically treated symptomatic carotid
disease, which allowed us, based on risk factors and degree
of stenosis, to precisely define the patients’ risk of stroke2
(Table I). NASCET allowed us to manage our symptom-
atic patients using evidence of the highest level.
Similarly, the Asymptomatic Carotid Atherosclerosis
Study (ACAS) provided us with a level 1 evidence basis for
making treatment recommendations in asymptomatic pa-
tients.4 Asymptomatic patients with60% stenosis derived
statistically significant benefit from CEA in the prevention
of ipsilateral stroke, as summarized in Table I.
The ACAS data have some issues that limit their use-
fulness as they are applied to individual patients. The ben-
efit of CEA, although statistically significant, is relatively
meager, with an absolute risk reduction of only 6% over 5
years. There was an unexplained sex difference in the ben-
efit of surgery, with men deriving more benefit than
women. Finally, there was no increase in the benefit of
surgery with increasing severity of disease, a finding clearly
at odds with the findings in NASCET.4 Still, the ACAS data
in general support a role for CEA in the management of
asymptomatic carotid disease. More recently, the Asymp-
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trial, confirmed the ACAS conclusion that endarterectomy
plus medical management was more beneficial than medical
management alone in the prevention of stroke in patients
with asymptomatic carotid stenosis.5
Critics of NASCET and ACAS, and those generally
skeptical of the benefits of CEA, have pointed to the ACAS
and NASCET exclusion criteria in suggesting that the data
from these studies apply to only a select group of patients.
These skeptics conclude (erroneously in my mind) that the
excluded patients will not benefit from CEA because of
increased operative risk or limited longevity. They argue
that the excluded patients a priori won’t benefit from CEA
but that they may benefit from stenting. I would argue that
many of these exclusion criteria, such as disabling stroke,
uncontrolled hypertension, and severe intracranial disease,
apply equally to endarterectomy and stenting; that others,
such as cardiac rhythm or valvular disorders, were used
simply to allow clear attribution of end point causation;
whereas still others, such as age and recent contralateral
CEA, were poorly thought out and probably unnecessary.
Other clinical investigators, though, have found that
medical risk factors really cannot define a group at high risk
for adverse outcomes from CEA. A study by Gasparis et al6
failed to show a significant CEA outcome difference when
outcomes in patients with established “high-risk” comor-
bidities were compared with outcomes in usual-risk pa-
tients.6
So, just as we got comfortable with the application of
the ACAS and NASCET findings in our individual prac-
tices, we began to learn of CAS as an alternative to CEA,
and the appeal of this minimally invasive, catheter-based
approach was undeniable. Early reports with the usual
remarkable “before and after” pictures revealing beautiful
results fueled early enthusiasm. The ease of performing the
procedure in high-anatomic-risk settings was undeniable.
Early registry results were encouraging. The early appeal of
CAS led to speculation about its potential role in the
management of anatomically and medically high-risk pa-
Table I. A, North American Symptomatic Carotid
Endarterectomy Trial and Asymptomatic Carotid
Atherosclerosis Study results summarized2,3,4
Trial
Medical
therapy, %
Medical therapy 
CEA, % P
NASCET
Ipsilateral stroke
At 2 y, 70%-99% 26 9 .001
At 5 y, 50%-70% 22.2 15.7 .045
At 5 y, 30%-50% 18.7 14.9 .16
ACAS
Ipsilateral stroke
At 5 y, 60% 11.0 5.1 .004
CEA, Carotid endarterectomy; NASCET, North American Symptomatic
Carotid Endarterectomy Trial; ACAS, Asymptomatic Carotid Atherosclero-
sis Study.tients and ultimately to speculation that it might replaceCEA as the default treatment for all patients with severe
carotid disease.
As experience with CAS increased nationally and inter-
nationally, publications of case series appeared, followed
quickly by several nonrandomized and then randomized
trials comparing stenting and endarterectomy (Table
II).7-17 I will now review these.
Roubin et al7 published a large multihospital registry
illustrating the safety and efficacy of CAS in which the
30-day stroke/death rate was 7.4% and the 3-year freedom
from ipsilateral or fatal stroke was 92%.7 In 2004, the
German Societies of Angiology and Radiology published
the largest registry of CAS, again suggesting a high level of
safety and technical success, with a combined stroke and
death rate of only 2.8% despite very significant variability in
equipment and technique.8
Three registries—Medtonics AVE Self-Expanding Ca-
rotid Stent System with Distal Protection in the Treatment
of Carotid Stenosis (MAVERiC), Carotid Stenting With
the Nexstent and Distal Protection With the FilterWire EX
in High Risk Patients (CABERNET), and Boston Scientific
EPI: A Carotid Stenting Trial for High-Risk Surgical Pa-
tients (BEACH)—were industry-sponsored attempts to
demonstrate safety and efficacy for United States Food and
Drug Administration approval for selected combinations of
stents, delivery systems, and cerebral protection devices.
MAVERiC evaluated the Medtronic carotid stent system
and found a major adverse event rate of 5% and a “proce-
dural success” rate of 90%.9 CABERNET evaluated the
Boston Scientific Filter wire used with the Nex-Stent stent
and delivery systems and found reasonable safety, with
30-day and 1-year adverse event rates of 3.9% and 11.9%,
respectively.10 In the BEACH registry, which evaluated use
of the Wallstent and Filterwire EX or EZ, the major adverse
event rate at 30 days was 5.8% and the procedural success
rate was 98%.11
The final registry I will discuss, ACCULINK for Revas-
cularization of Carotids in High-Risk Patients (ARCHeR),
is both the most compelling and at the same time, the most
Table I. B, North American Symptomatic Carotid
Endarterectomy Trial risk factors for stroke at 2 years in
patients managed without surgery
Factor Stroke risk at 2 years %
Age 70 Risk by factors
SBP 160 mm Hg 0-5 factors 17
DBP 90 mm Hg 6 factors 23
Recent CVA 6 factors 39
Stenosis80%
Ulceration on arteriogram Risk by carotid stenosis
History of tobacco use 70%-79% 12
Diabetes 80%-89% 18
Claudication 90%-99% 26
Hyperlipidemia
SBP, systolic blood pressure; DBP, diastolic blood pressure; CVA, cerebro-
vascular accident.misleading of these industry-sponsored trials.12 This regis-
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cerebral protection systems. By design, this was a large
registry of high-risk patients that incorporated well-
documented eligibility criteria. The results are credible,
although not as promising as those of prior registries, with
an overall 30-day stroke/death/myocardial infarction
(MI) rate of 13% in symptomatic patients, 6.8% in asymp-
tomatic patients, and 8.3% overall. However, the credibility
of this study ends when the authors introduce their “con-
trol group,” a historical series of high-risk CEA patients
including patients undergoing combined coronary artery
bypass grafting/CEA. The authors calculate a control
group composite adverse event rate of14%, which makes
the composite adverse event rate in the stent group (8.3%
overall but 13% in symptomatic patients) look favorable.
Where in the literature in the past 20 years have we seen
any study of carotid surgery in which the 30-day adverse
event rate was 14%? To my mind, the publication of this
article with inclusion of the historical composite control
group was a failure of the Journal of Vascular Surgery
editorial process. The inclusion of this control group is even
more egregious given potential conflict of interest in this
study because most authors were Guidant employees or
consultants. In addition, 76% of the patients entered were
asymptomatic. With a periprocedural adverse event rate of
6.8%, the asymptomatic patients might well have fared
better with medical therapy alone.
Now I will move from registries to comparative trials.
The Carotid Revascularization using Endarterectomy or
Stenting Systems (CaRESS) trial was an industry-
sponsored (Boston Scientific and Medtronic) nonrandom-
ized comparative trial.13 Patients received CEA or CAS on
the basis of recommendations by their physicians or their
own preference. The results revealed no significant differ-
ences in 30-day or 1-year outcomes, although there was a
nonstatistically significant trend toward better outcomes in
the stent group.
Of course, in this industry-sponsored nonrandomized
study, the potential for selection bias is very real, and the
findings, therefore, are difficult to interpret. Still, it would
appear from these data that CAS represents a reasonably
safe procedure that has a significant role in the management
of some patients with carotid disease. Still, because patients
were assigned to treatments on the basis of some combina-
tion of the recommendations of their physicians and on
their preference, we can never know which patients are
better served by stenting and which by endarterectomy.
Prospective randomized trials usually provide the high-
est level of evidence and should allow for truly evidence-
based decision making. Unfortunately, the peculiar charac-
teristics of the existing randomized trials comparing CEA
and CAS do not really permit generalizable conclusions
regarding their relative merits. The Carotid and Vertebral
Artery Transluminal Angioplasty Study (CAVATAS) was
the first randomized trial, but included both carotid and
vertebral disease patients, plain old balloon angioplasty
with little use of stents, no cerebral protection device use,
and had high morbidity and mortality rates in both thesurgical and interventional arms.14 This trial is of little
relevance today.
Perhaps the stent vs endarterectomy trial that caused
the biggest splash, at least initially, was the Stenting and
Angioplasty with Protection in Patients at High Risk for
Endarterectomy (SAPPHIRE) trial.15 This randomized
trial, sponsored by Cordis, compared the outcomes of CEA
and stenting in patients at high risk for CEA. Without peer
review, the initial results were published in USA Today and
were widely misinterpreted. The primary end point for the
SAPPHIRE trial, after peer review and publication in the
New England Journal of Medicine, was an amalgam of
short- and intermediate-term results (periprocedural
stroke, MI, or death and 1-year ipsilateral stroke or death).
Analyzed in this way, the results for stenting were statisti-
cally significantly superior to those of CEA (P  .05).
However, there was no statistically significant difference in
outcome in any individual end point of death, stroke, or
MI. Furthermore, 15 of 17 MIs encountered overall and 10
of 12 MIs in the CEA group were non-Q-wave events of
doubtful significance.
Perhaps most importantly, this trial may not reflect
real-world decision making. Less than 30% of these “high-
risk” patients had symptomatic carotid disease. In most
practices, many of these asymptomatic patients would have
been followed conservatively, probably with a very low
incidence of stroke. The failure of the SAPPHIRE group to
include a medical management arm makes their overall
results largely irrelevant to current practice and hints at the
true motivation behind this study. I will offer more of my
thoughts on this motivation in a moment.
Randomized controlled trials comparing patients
equally eligible for either CEA or CAS would seem, at least
to me, to be the best way to evaluate the relative merits of
these two treatments. A large enough trial might even have
the statistical power to permit subgroup analysis so we
could really learn something about who is likely to benefit
most from CEA and who is likely to benefit most from
CAS. Recently, two European trials have been published in
which results of CEA and CAS in patients equally eligible
for these alternative treatments were compared.
First, the Endarterectomy Versus Angioplasty in Pa-
tients With Symptomatic Severe Carotid Stenosis (EVA-
3S) trial compared the outcome of CEA and CAS in 527
patients with severe symptomatic carotid stenosis.16 The
30-day results revealed stroke/death rates of 3.9% in the
CEA group and 9.6% in the stent group (P .01), and the
6-month results revealed stroke death rates of 6.1% in the
CEA group and 11.7% in the CAS group (P .02). Critics
of this study point to several flaws, including the inclusion
of 20 patients done without cerebral protection in whom
there was a 25% stroke incidence, the diversity of stents and
cerebral protection devices used, and differences in the
experience levels of the surgeons and interventionalists.
Similarly, the Stent-Protected Percutaneous Angio-
plasty Versus Carotid Endarterectomy (SPACE) trial com-
pared outcomes in 1185 symptomatic patients randomized
to CAS or CEA.17 This trial, which was designed as a
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CAS compared with CEA in these patients. SPACE is
criticized for the use of cerebral protection in only 27% of
the CAS patients. Of interest, the entire outcome difference
was confined to the subgroup of patients aged 75 years
old. Those aged 75 fared equally with CEA and CAS.
Perhaps the most awaited trial results since those of
NASCET and ACAS are the results eagerly anticipated
from the Carotid Revascularization Endarterectomy vs.
Stent Trial (CREST), a randomized trial comparing stent-
ing and endarterectomy in 2500 subjects deemed equally
eligible for either treatment. The results of the lead-in
phase of this trial suggest that age plays a significant role in
outcome of CAS, with older patients having much worse
CAS outcomes than younger patients.18 These results are
consistent with the findings of the SPACE trial.
One additional study deserves mention because it rep-
resents a good faith effort to identify subgroups of patients
for whom stenting might be the preferred treatment and
others for whom endarterectomy might be the preferred
treatment. The Imaging in Carotid Angioplasty and Risk of
Stroke (ICAROS) trial analyzed stent outcomes according
to gray-scale median (GSM) measurements.19 GSM repre-
sents a measure of plaque echogenicity. Low GSM plaques
are those with a large lipid core or intraplaque hemorrhage,
whereas higher GSM plaques are those with predominantly
fibrous or calcific composition. In this study, patients with
GSM of 25 had a periprocedural stroke risk of 7.1%,
whereas those with GSM 25 had a periprocedural stroke
risk of only 1.5%. Of note is that cerebral protection seemed
Table II. Representative clinical studies of carotid artery
stenting
Registries
● Roubin, et al7
● Pro-CAS8
● MAVErIC9
● CABERNET10
● BEACH11
● ARCHER12
Nonrandomized comparative trials
● CaRESS13
Randomized comparative trials
● CAVATAS14
● CREST18
● SAPPHIRE15
● EVA-3S16
● SPACE17
MAVEriC, Medtronic AVE Self- Expanding Carotid Stent System with
Distal Protection in the Treatment of Carotid Stenosis; CABERNET,
Carotid Artery Revascularization Using the Boston Scientific EPI FilterWire
EX/EZ and the EndoTex NexStent; BEACH, Boston Scientific EPI: A
Carotid Stenting Trial for High Risk Surgical Patients; ARCHeR, ACCU-
LINK for Revascularization of Carotids in High-Risk Patients; CARESS,
Carotid Revascularization using Endarterectomy or Stenting Systems; CA-
VATAS, Carotid and Vertebral Artery Transluminal Angioplasty Study;
SAPPHIRE, Stenting and Angioplasty with Protection in Patients at High
Risk for Endarterectomy; EVA-3S, Endarterectomy Versus Angioplasty in
Patients With Symptomatic Severe Carotid Stenosis; SPACE, Stent-
Protected Percutaneous Angioplasty Versus Carotid Endarterectomy.ineffective in patients with very low GSM.So, where does this leave us? The situations in which
CAS was initially deemed intuitively appropriate in the
management for carotid disease are summarized in Table
III. I would submit to you that despite all of the trials we
have reviewed (and a few more which time did not permit
us to review), our appreciation of the role of CAS now is no
more sophisticated than it was 5 years ago. Why?
What we have learned is that CAS is both feasible and
reasonably safe, yielding satisfactory short- and intermediate-
term results. In addition, although not covered in this talk in
detail, restenosis rates seem acceptable at an intermediate term
of 1 to 3 years. On the other hand, what we have yet to learn
is much more important. In which patients is stenting pre-
ferred over endarterectomy? In which patients is endarterec-
tomy preferred over stenting? And, perhaps most importantly,
what is the impact of newer drugs, especially statins and
clopidogrel, on the role of intervention and on the indications
for medical management? Why have we not yet learned which
treatment is best in which patient?
Current trials have really been designed to tell us
whether endarterectomy or stenting is superior in large
groups of patients with rather broadly defined risk criteria
and other characteristics. They have not been designed to
explore potentially complementary roles for stenting, end-
arterectomy, and medical treatment. Because it is virtually
certain that some patients will be best served by endarter-
ectomy, others by stenting, and still others by medical
therapy alone, why are there no trials specifically designed
to promote the development of rational treatment guide-
lines or standards?
I believe that the answer to this question lies in the
economics of carotid disease treatment. First, it is clear that
device manufacturers have spent very large amounts of
money to engineer, manufacture, and study stents, delivery
systems, and protection devices. For them, having CAS
turn out to be a niche treatment for only a select subset of
carotid disease patients would be a disaster. To recoup their
investment, they need for stenting to be the default in
carotid disease management.
Second, vascular surgeons, a small and under-
represented group, and our patients are really the only
stakeholders in carotid disease management that can
afford to be objective and to look at stenting as an
interesting and potentially complementary treatment
preferred for some yet to be defined segment of the
carotid disease population. We, as vascular surgeons, can
Table III. Currently accepted indications for carotid
stenting
● Early recurrent stenosis
● Hostile heck (radiation, radical neck dissection, tracheostomy,
infection)
● Surgically inaccessible lesion
● Fibromuscular dysplasia
● Inclusion in approved randomized controlled trial
● Extreme medical risk (hard to define precisely)offer endarterectomy, carotid stenting, and medical ther-
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objective in assessing the relative merits of each of these
treatments in each individual patient. Interventional car-
diologists can offer only medical therapy or stenting, and
interventional radiologists only stenting. When your
only tool is a hammer, the whole world looks like a nail,
or in the immortal words of a former partner “Go to
Midas, get a muffler!”
All the evidence I need in support of my interpretation
of the motivation for carotid stent trial design is seen in this
headline from the November 2006 issue of Vascular News.
This headline “Setback For Carotid Stenting?” followed
publication of the EVA-3S and SPACE trials in which
stenting came out second best compared with endarterec-
tomy. If the editors of this publication were interested in
furthering our understanding of the optimal management
of patients with carotid disease, the headline would have
been very different, perhaps something like: “Are EVA-3S
and SPACE Results Valid?” or “EVA-3S and SPACE:
Should They Influence Carotid Disease Management?” In
the chosen headline, the editors decided to interpret the
results of EVA-3S and SPACE as potential threats to ca-
rotid stenting and to those whose interests are aligned with
carotid stenting, rather than as potential advances in patient
management. The primacy of economic concern over con-
cern for scientific merit or patient welfare is evident.
Where do we go, then, with trial design in assessing the
future roles of medical management, carotid stenting, and
carotid endarterectomy? I believe that all future trials
should be designed with the assumption that some patients
will be best managed medically, some with medical therapy
plus stenting, and some with medical therapy plus endar-
terectomy. These treatments are complementary and not
competing. Varying treatment algorithms including more
or less liberal use of each modality can be designed, patients
randomly assigned to one of the algorithms, and their
results compared. For example, if we use experience as our
guide, we might come up with a management algorithm
that looks something like Table IV. At present, such an
algorithm lacks evidentiary support. We could, however,
randomly assign large numbers of patients to be managed
according to this paradigm and compare their outcomes
with patients randomized to alternative schemes that in-
clude more liberal or conservative use of stenting, of med-
Table IV. One potential carotid treatment algorithm for c
Carotid endarterectomy ( medical management) Carotid st
Age 80 Hostile nec
Low or very high gray-scale median Recurrent
Extreme tortuosity High lesion
Difficult arterial access Specified c
Contrast allergy or renal issue Contralate
Clopidogrel and ticlopidine contraindicated History of
anesthet
Significant arch diseaseical management, or of endarterectomy. In this way overtime, we could develop a much more robust understanding
of the appropriate place of our three potential treatments
for carotid disease.
I would like to close with a cautionary note. At present,
the needs of industry and of other self-interested parties are
framing the way in which we evaluate carotid artery stent-
ing and compare it with medical management and with
carotid endarterectomy. Their interests have not only bi-
ased the reports of these evaluations, but in fact, have also
dictated the very questions that are being asked about these
treatments. No one is protecting the interests of our pa-
tients because no one is asking the question, “What treat-
ment program is optimal?” We are only asking the ques-
tion, “Is stenting better than endarterectomy?” because in
the answer to this question lies the greatest potential to
further industrial and other interests. In 1961, the 34th
President of the United States, Dwight Eisenhower, gave
his farewell address and warned against the rising power of
the military-industrial complex, who by feeding off of the
public’s general xenophobia and paranoia regarding com-
munism, threatened to define our military’s needs in a way
that would both empower the military and further fatten
the wallets of those in the defense industry. He stated, “In
the councils of government, we must guard against the
acquisition of unwarranted influence, whether sought or
unsought, by the military-industrial complex. The potential
for the disastrous rise of misplaced power exists and will
persist.”20
I would submit that this quotation is highly relevant
to the current situation with carotid stenting if we sub-
stitute the words “practice of surgery” for the words
“councils of government” and the word “medical” for
the word “military.” My revised cautionary note would
then read: “In the practice of surgery, we must guard
against the acquisition of unwarranted influence, whether
sought or unsought, by the medical-industrial complex.
The potential for the disastrous rise of misplaced power
exists and will persist.”
Our patients deserve an unbiased evaluation of the
currently available options for the treatment of carotid
disease. We must protect their interests by taking the lead in
such studies. I thank you for your attention and for the
arison with alternative algorithms in future clinical trials
( medical management) Medical management alone
Limited life expectancy
sis Age 90
Asymptomatic patient on dialysis
risk Defined extreme medical risk
nial nerve palsy
nant hyperthermia or other
eomp
enting
k
steno
ardiac
ral cra
malig
ic issuprivilege of serving as your president.
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